Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Laura Runkel

Associate Director

About Laura

USA

+32 year(s) experience

Associate Director Laura Runkel supports clinical trial intelligence for the autoimmune/inflammation, CNS and ophthalmology therapeutic areas. She tracks drug development and related clinical trials to prepare analytical reports and provide clients with direct insights.

In addition to supporting content for the broad areas of autoimmune/inflammation, CNS, Ophthalmology diseases, Laura's specialities include biosimilar programs for autoimmune and inflammatory indications and drug programs for asthma, COPD, lupus, rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

Prior to joining Citeline in 2006, Laura gained research experience in liver pathologies (HBV, fibrosis), and cytokine/interferon pathologies/function, both of which have deepened the insights she can provide to our pharma clients interested in these areas.

Specialties

CNS
Immunology & Inflammation
Clinical Trials

Laura Writes For

Trialtrove: gold standard clinical trials intelligence

Citeline, Citeline Analytics

2017 Completed Clinical Trials: Status Quo or No Webinar Recording

By Laura Runkel 08 Nov 2018

For a deeper look into the data behind last year’s completed clinical trials and the trends driving them, Listen to the Completed Clinical Trials 2017: Status Quo or No?

Topic Clinical trials

Full video
Citeline, Trialtrove

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

By Laura Runkel 19 Oct 2018

Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.

View white paper
Trialtrove

The Coming of Age of Biosimilars in Autoimmune and Inflammatory Diseases

By Laura Runkel 19 Jun 2017

Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years.

Topic Biosimilars

View white paper
Trialtrove

What is new for refractory asthma therapies?

By Laura Runkel 09 Jan 2017

The past year has seen the approval of the first biologic drugs for the treatment of severe eosinophilic asthma, the anti-IL5 antibodies Cinquar (Teva) and Nucala (GlaxoSmithKline, GSK).

Topic Clinical trials Drug approval Clinical trial optimization

Read blog
Citeline

Neonatal Brain Injury: A new addition to Citeline’s portfolio

By Laura Runkel 29 Jan 2016

Citeline’s Trialtrove has recently expanded its disease coverage to include trials evaluating therapeutic treatments for neonatal brain injury.

Topic Diseases

Read blog
Citeline

BAFF inhibition comes up short – How might study design explain the disappointing SLE outcomes of Lilly’s tabalumab trials?

By Laura Runkel 24 Oct 2014

The recent discontinuation of Eli Lilly’s tabalumab quickly followed the completion of two pivotal trials, ILLUMINATE 1 and 2.

Topic Clinical trials

Read blog
Pharmaprojects

FDCs for COPD: From Famine to a Feast of Therapeutic Choices

By Laura Runkel 01 Jan 2014

A report on the treatment of chronic obstructive pulmonary disease (COPD)

Topic Clinical trials

View white paper

Latest headlines from Laura

Pink Sheet

10 May 2016

Mandatory Education For Advisory Committee Members?

Link
Pink Sheet

20 Apr 2016

NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns

Link
Pink Sheet

19 Apr 2016

A “Precedent-Setting” OTC Switch – And A Case Study In Disregarding FDA’s Advice

Link
Pink Sheet

16 Feb 2016

FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs

Link
Scrip

16 Dec 2015

Steps On The Long Road To Therapies For Uncontrolled Asthma

Link
Pink Sheet

15 Dec 2015

Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say

Link
Pink Sheet

17 Nov 2015

Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome

Link
Pink Sheet

26 Oct 2015

FDA’s Woodcock Cautions Against Trying To “Legislate A New Generation Of Biomarkers”

Link
Pink Sheet

21 Oct 2015

FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

Link
Pink Sheet

14 Oct 2015

Help Wanted: FDA Recruiting New CBER Director Ahead Of Gene, Cell Therapy Wave

Link
Pink Sheet

03 Sep 2015

Clinton Campaign “Combating Addiction” Initiative: One Hillary Rx Policy Industry Could Support

Link
Pink Sheet

14 Aug 2015

FDA Prepares For LPAD: Orphan Drug Approvals Are Model

Link
Pink Sheet

12 Aug 2015

CMS Denial of Astellas’ Cresemba Add-On Payment Could Boost Legislative Solution

Link
Pink Sheet

12 Aug 2015

Hard Feelings: Allergan/Valeant Merger Fight Colors Tax Reform Hearing

Link
Pink Sheet

22 Jul 2015

CMS Nursing Homes Regs Include Controls For Antibiotics And “Psychotropic” Drugs

Link

Laura Runkel

About Laura

Analyst Articles

Articles by Laura

2017 Completed Clinical Trials: Status Quo or No Webinar Recording

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

The Coming of Age of Biosimilars in Autoimmune and Inflammatory Diseases

What is new for refractory asthma therapies?

Neonatal Brain Injury: A new addition to Citeline’s portfolio

BAFF inhibition comes up short – How might study design explain the disappointing SLE outcomes of Lilly’s tabalumab trials?

FDCs for COPD: From Famine to a Feast of Therapeutic Choices

Latest headlines from Laura

Mandatory Education For Advisory Committee Members?

NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns

A “Precedent-Setting” OTC Switch – And A Case Study In Disregarding FDA’s Advice

FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs

Steps On The Long Road To Therapies For Uncontrolled Asthma

Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say

Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome

FDA’s Woodcock Cautions Against Trying To “Legislate A New Generation Of Biomarkers”

FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

Help Wanted: FDA Recruiting New CBER Director Ahead Of Gene, Cell Therapy Wave

Clinton Campaign “Combating Addiction” Initiative: One Hillary Rx Policy Industry Could Support

FDA Prepares For LPAD: Orphan Drug Approvals Are Model

CMS Denial of Astellas’ Cresemba Add-On Payment Could Boost Legislative Solution

Hard Feelings: Allergan/Valeant Merger Fight Colors Tax Reform Hearing

CMS Nursing Homes Regs Include Controls For Antibiotics And “Psychotropic” Drugs